Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

被引：0
|
作者：
De Miguel, M. [1 ]
Landa Magdalena, A. [2 ]
Moreno Garcia, V. [3 ]
Gambardella, V. [4 ]
Menis, J. [5 ]
Daniele, G. [6 ]
El-Khoueiry, A. B. [7 ]
Spira, A. I. [8 ]
Gravina, A. [9 ,10 ]
Olszanski, A. J. [11 ]
Rapaic, O. [12 ]
Li, J. [13 ]
Poullain, H. [14 ]
Margall, G. [14 ]
Wong, G. [15 ]
Hedrich, W. [16 ]
Pollard, J. Russella [15 ]
Gan, J. [17 ]
Shi, X. [18 ]
Andtbacka, R. H. I. [19 ]
机构：
[1] Hosp Univ HM Sanchinarro, CIOCC Ctr Integral Oncol Clara Campal, Early Phase Clin Trial Unit, Madrid, Spain
[2] Clin Univ Navarra, Dept Med Oncol, Madrid, Spain
[3] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[4] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
[5] AOU Integrata Verona Osped Borgo Roma, Med Oncol, Verona, Italy
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Phase Unit 1, Rome, Italy
[7] USC Univ Southern Calif, Keck Sch Med, Med Oncol Div, Los Angeles, CA USA
[8] Virginia Canc Specialist, Res Dept, Fairfax, VA USA
[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Ric Traslaz, Naples, Italy
[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Serv Percorsi Oncol, Naples, Italy
[11] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA
[12] HiFiBiO Inc, Clin Operat, Cambridge, MA USA
[13] HiFiBiO Therapeut Inc, Dis Biol, Cambridge, MA USA
[14] HiFiBio SAS, Translat Med, Paris, France
[15] HiFiBiO Therapeut Inc, Translat Med, Cambridge, MA USA
[16] HiFiBiO Therapeut Inc, Clin Pharmacol, Cambridge, MA USA
[17] HiFiBiO Therapeut Inc, Res, Cambridge, MA USA
[18] HiFiBiO Therapeut, Clin Dev, Shanghai, Peoples R China
[19] HiFiBiO Therapeut Inc, Clin Dev, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1006P
引用
收藏
页码：S684 / S684
页数：1
相关论文
共 50 条
  • [21] A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
    El-Khoueiry, Anthony B.
    Garralda, Elena
    Cervantes, Andres
    Haddox, Candace L.
    Babiker, Hani M.
    Borad, Mitesh J.
    Leventakos, Konstantinos
    Mehra, Ranee
    Zugazagoitia, Jon
    Hanna, Diana L.
    Alonso, Guzman
    Liu, Angela
    Shi, Xiaorong
    Pollard, Jack Russella
    Wong, Gabrielle
    Hedrich, William
    Lin, Xi
    Hatzis, Christos
    Pallante, John
    Andtbacka, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
    Liu, Dan
    Gong, Jifang
    Zhang, Jian
    Shu, Yongqian
    Wu, Hao
    Liu, Tianshu
    Xu, Yanhua
    Zhang, Lijia
    Li, Min
    Hu, Xichun
    Shen, Lin
    INVESTIGATIONAL NEW DRUGS, 2025, : 250 - 261
  • [23] Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
    Desai, Jayesh
    Meniawy, Tarek
    Beagle, Brandon
    Li, ZheZhen
    Mu, Song
    Wu, John
    Denlinger, Crystal S.
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
    Glisson, B. S.
    Leidner, R.
    Ferris, R. L.
    Powderly, J.
    Rizvi, N.
    Norton, J. D.
    Burton, J.
    Lanasa, M. C.
    Patel, S. P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [26] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and doseexpansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Horvath, L.
    Desai, J.
    Sandhu, S.
    O'Donnell, A.
    Hill, A. G.
    Deva, S.
    Markman, B.
    Jameson, M. B.
    Chen, Z.
    Tan, X.
    Hou, J.
    Lim, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
    Desai, J.
    Voskoboynik, M.
    Markman, B.
    Hou, J.
    Zeng, D.
    Meniawy, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 146 - 146
  • [29] PHASE 1 TRIAL OF FIRST-IN-CLASS ANTI-CD96 MONOCLONAL ANTIBODY INHIBITOR, GSK6097608, MONOTHERAPY AND COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY, DOSTARLIMAB, IN ADVANCED SOLID TUMORS
    Hamid, Omid
    Baxter, Dawn
    Easton, Rachael
    Siu, Lilian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A518 - A518
  • [30] A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
    Desai, Jayesh
    Davar, Diwakar
    Deva, Sanjeev
    Gao, Bo
    Liu, Tianshu
    Matos, Marco
    Meniawy, Tarek
    O'Byrne, Kenneth John
    Sun, Meili
    Voskoboynik, Mark
    Yang, Kunyu
    Yu, Xinmin
    Chen, Xin
    Dong, Yan
    Giovinazzo, Hugh
    Leaw, Shiangjiin
    Patel, Deepa
    Rahman, Tahmina
    Wu, Yanjie
    Day, Daphne
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345